• All treatment
• antibody–drug conjugate
• trastuzumab emtansine
• trastuzumab emtasine plus endocrine therapy
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus endocrine therapy
• palbociclib based treatment
• palbociclib
• palbociclib plus endocrine therapy
• HER inhibitor
• HER2 inhibitor
• neratinib based treatment
• neratinib
• pertuzumab based treatment
• pertuzumab plus trastuzumab
• trastuzumab based treatment
• docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab alone
• mTOR inhibitors
• everolimus
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib

• versus all
• vs chemotherapy
• vs doxorubicin plus cyclophosphamide followed by docetaxel
• vs Standard of Care (SoC)
• vs endocrine therapy
• vs HER inhibitor
• vs HER2 inhibitor
• vs trastuzumab based treatment
• vs docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• vs trastuzumab
• vs non active control
• vs placebo

  Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only